Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.
Sainz de la Maza SPaulette Esperanza Walo-DelgadoMario Rodríguez-DomínguezEnric MonrealAlexander Rodero-RomeroJuan Luis ChicoRoberto Pariente-RodríguezFernando Rodríguez-JorgeRubén Ballester-GonzálezNoelia VillarrubiaBeatriz Romero-HernándezJaime Masjuan VallejoLucienne CostaLuisa Maria VillarPublished in: Vaccines (2023)
SARS-CoV-2 vaccines induce robust and long-lasting humoral and cell-mediated specific immune responses in most patients with MS.